Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder that causes extremely elevated plasma triglyceride levels, with limited therapeutic options. Volanesorsen is an antisense oligonucleotide approved for its treatment. A 24-year-old woman with genetically diagnose...
- Autores:
-
Isaac, Rafael H.
Gonzalez-Devia, Deyanira
Mendivil, Carlos O.
Chapman, Edgardo
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2023
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/11154
- Acceso en línea:
- http://hdl.handle.net/20.500.12495/11154
https://doi.org/10.3389/falgy.2023.1201807
- Palabra clave:
- Reacciones adversas
Síndrome de quilomicronemia familiar
Pancreatitis
Triglicéridos
Urticaria
Volanesorsen
Adverse reactions
Familial chylomicronemia syndrome
Pancreatitis
Triglycerides
Urticaria
Volanesorsen
- Rights
- openAccess
- License
- Atribución 4.0 Internacional
id |
UNBOSQUE2_c17740d95c2277ed3b3a1be0b05305d4 |
---|---|
oai_identifier_str |
oai:repositorio.unbosque.edu.co:20.500.12495/11154 |
network_acronym_str |
UNBOSQUE2 |
network_name_str |
Repositorio U. El Bosque |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen |
title |
Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen |
spellingShingle |
Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen Reacciones adversas Síndrome de quilomicronemia familiar Pancreatitis Triglicéridos Urticaria Volanesorsen Adverse reactions Familial chylomicronemia syndrome Pancreatitis Triglycerides Urticaria Volanesorsen |
title_short |
Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen |
title_full |
Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen |
title_fullStr |
Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen |
title_full_unstemmed |
Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen |
title_sort |
Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen |
dc.creator.fl_str_mv |
Isaac, Rafael H. Gonzalez-Devia, Deyanira Mendivil, Carlos O. Chapman, Edgardo |
dc.contributor.author.none.fl_str_mv |
Isaac, Rafael H. Gonzalez-Devia, Deyanira Mendivil, Carlos O. Chapman, Edgardo |
dc.subject.spa.fl_str_mv |
Reacciones adversas Síndrome de quilomicronemia familiar Pancreatitis Triglicéridos Urticaria Volanesorsen |
topic |
Reacciones adversas Síndrome de quilomicronemia familiar Pancreatitis Triglicéridos Urticaria Volanesorsen Adverse reactions Familial chylomicronemia syndrome Pancreatitis Triglycerides Urticaria Volanesorsen |
dc.subject.keywords.spa.fl_str_mv |
Adverse reactions Familial chylomicronemia syndrome Pancreatitis Triglycerides Urticaria Volanesorsen |
description |
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder that causes extremely elevated plasma triglyceride levels, with limited therapeutic options. Volanesorsen is an antisense oligonucleotide approved for its treatment. A 24-year-old woman with genetically diagnosed FCS secondary to a pathogenic variant in APOA5 and a history of recurrent hypertriglyceridemia-induced pancreatitis episodes was being treated with volanesorsen, 285 mg every 2 weeks. Treatment with volanesorsen achieved normalization of triglycerides to <200 mg/dl. However, after the fifth dose of the medication, the patient developed urticaria and volanesorsen was discontinued. In the absence of alternative pharmacological treatments, the patient received a novel desensitization protocol for volanesorsen that allowed continuation of therapy, without evidence of hypersensitivity reactions after subsequent administrations. FCS requires aggressive multimodal therapy and close follow-up. Volanesorsen has shown great efficacy, but a significant rate of discontinuation due to side effects has been observed. Here, the patient presented an immediate hypersensitivity reaction to volanesorsen, but the provision of a desensitization protocol was effective, facilitating continued treatment and impacting the survival and quality of life of the patient. |
publishDate |
2023 |
dc.date.accessioned.none.fl_str_mv |
2023-07-25T17:06:32Z |
dc.date.available.none.fl_str_mv |
2023-07-25T17:06:32Z |
dc.date.issued.none.fl_str_mv |
2023 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.local.none.fl_str_mv |
Artículo de revista |
dc.type.hasversion.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.coar.none.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.driver.none.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.coarversion.none.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
format |
http://purl.org/coar/resource_type/c_6501 |
status_str |
publishedVersion |
dc.identifier.issn.none.fl_str_mv |
2673-6101 |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12495/11154 |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.3389/falgy.2023.1201807 |
dc.identifier.instname.spa.fl_str_mv |
instname:Universidad El Bosque |
dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional Universidad El Bosque |
dc.identifier.repourl.none.fl_str_mv |
repourl:https://repositorio.unbosque.edu.co |
identifier_str_mv |
2673-6101 instname:Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque repourl:https://repositorio.unbosque.edu.co |
url |
http://hdl.handle.net/20.500.12495/11154 https://doi.org/10.3389/falgy.2023.1201807 |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofseries.spa.fl_str_mv |
Frontiers in Allergy, 2673-6101, 4, 2023, 1-5 |
dc.relation.uri.none.fl_str_mv |
https://www.frontiersin.org/articles/10.3389/falgy.2023.1201807/full |
dc.rights.*.fl_str_mv |
Atribución 4.0 Internacional |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/4.0/ |
dc.rights.local.spa.fl_str_mv |
Acceso abierto |
dc.rights.accessrights.none.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ Acceso abierto http://purl.org/coar/access_right/c_abf2 |
eu_rights_str_mv |
openAccess |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Frontiers in Allergy |
dc.publisher.journal.spa.fl_str_mv |
Frontiers in Allergy |
institution |
Universidad El Bosque |
bitstream.url.fl_str_mv |
https://repositorio.unbosque.edu.co/bitstreams/45182595-6f29-40bf-9ba5-784c5d4bda5c/download https://repositorio.unbosque.edu.co/bitstreams/c7f40a30-332b-4d03-b0d4-509598d08b21/download https://repositorio.unbosque.edu.co/bitstreams/1e0565f6-ff83-406e-b5d0-2e00709d08aa/download https://repositorio.unbosque.edu.co/bitstreams/b0ff0ee6-d7ad-4362-b117-f1c8f4d3acb5/download https://repositorio.unbosque.edu.co/bitstreams/94437f7e-65d5-4831-8eda-d12c5aabe0b9/download |
bitstream.checksum.fl_str_mv |
79715fa43aa00e4e683ae79d5b7e85bc 0175ea4a2d4caec4bbcc37e300941108 17cc15b951e7cc6b3728a574117320f9 de938094d9b524b6402e8ab8a2374948 9ccc526b7589fbdd39eda642a9648867 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad El Bosque |
repository.mail.fl_str_mv |
bibliotecas@biteca.com |
_version_ |
1828164474280869888 |
spelling |
Isaac, Rafael H.Gonzalez-Devia, DeyaniraMendivil, Carlos O.Chapman, Edgardo2023-07-25T17:06:32Z2023-07-25T17:06:32Z20232673-6101http://hdl.handle.net/20.500.12495/11154https://doi.org/10.3389/falgy.2023.1201807instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengFrontiers in AllergyFrontiers in AllergyFrontiers in Allergy, 2673-6101, 4, 2023, 1-5https://www.frontiersin.org/articles/10.3389/falgy.2023.1201807/fullAtribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/Acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessReacciones adversasSíndrome de quilomicronemia familiarPancreatitisTriglicéridosUrticariaVolanesorsenAdverse reactionsFamilial chylomicronemia syndromePancreatitisTriglyceridesUrticariaVolanesorsenCase report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsenArtículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttp://purl.org/coar/version/c_970fb48d4fbd8a85Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder that causes extremely elevated plasma triglyceride levels, with limited therapeutic options. Volanesorsen is an antisense oligonucleotide approved for its treatment. A 24-year-old woman with genetically diagnosed FCS secondary to a pathogenic variant in APOA5 and a history of recurrent hypertriglyceridemia-induced pancreatitis episodes was being treated with volanesorsen, 285 mg every 2 weeks. Treatment with volanesorsen achieved normalization of triglycerides to <200 mg/dl. However, after the fifth dose of the medication, the patient developed urticaria and volanesorsen was discontinued. In the absence of alternative pharmacological treatments, the patient received a novel desensitization protocol for volanesorsen that allowed continuation of therapy, without evidence of hypersensitivity reactions after subsequent administrations. FCS requires aggressive multimodal therapy and close follow-up. Volanesorsen has shown great efficacy, but a significant rate of discontinuation due to side effects has been observed. Here, the patient presented an immediate hypersensitivity reaction to volanesorsen, but the provision of a desensitization protocol was effective, facilitating continued treatment and impacting the survival and quality of life of the patient.ORIGINALfalgy-04-1201807.pdffalgy-04-1201807.pdfCase report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsenapplication/pdf7139389https://repositorio.unbosque.edu.co/bitstreams/45182595-6f29-40bf-9ba5-784c5d4bda5c/download79715fa43aa00e4e683ae79d5b7e85bcMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908https://repositorio.unbosque.edu.co/bitstreams/c7f40a30-332b-4d03-b0d4-509598d08b21/download0175ea4a2d4caec4bbcc37e300941108MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82000https://repositorio.unbosque.edu.co/bitstreams/1e0565f6-ff83-406e-b5d0-2e00709d08aa/download17cc15b951e7cc6b3728a574117320f9MD53THUMBNAILfalgy-04-1201807.pdf.jpgfalgy-04-1201807.pdf.jpgIM Thumbnailimage/jpeg8306https://repositorio.unbosque.edu.co/bitstreams/b0ff0ee6-d7ad-4362-b117-f1c8f4d3acb5/downloadde938094d9b524b6402e8ab8a2374948MD54TEXTfalgy-04-1201807.pdf.txtfalgy-04-1201807.pdf.txtExtracted texttext/plain21850https://repositorio.unbosque.edu.co/bitstreams/94437f7e-65d5-4831-8eda-d12c5aabe0b9/download9ccc526b7589fbdd39eda642a9648867MD5520.500.12495/11154oai:repositorio.unbosque.edu.co:20.500.12495/111542024-02-07 02:40:58.777http://creativecommons.org/licenses/by/4.0/Atribución 4.0 Internacionalopen.accesshttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.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 |